- Home
- CB vs GNLX Comparison
CB vs GNLX Comparison
Compare CB & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CB | GNLX |
|---|---|---|
| Founded | 1985 | 2001 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.9B | 133.0M |
| IPO Year | 1995 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CB | GNLX |
|---|---|---|
| Price | $338.79 | $2.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 4 |
| Target Price | ★ $332.76 | $17.25 |
| AVG Volume (30 Days) | ★ 1.5M | 166.1K |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | ★ 13.13 | 9.47 |
| EPS | ★ 5.88 | N/A |
| Revenue | ★ $59,402,000,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.31 | N/A |
| P/E Ratio | $56.29 | ★ N/A |
| Revenue Growth | ★ 6.54 | N/A |
| 52 Week Low | $264.10 | $2.29 |
| 52 Week High | $345.67 | $8.54 |
Technical Indicators
Market Signals| Indicator | CB | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.04 | 43.39 |
| Support Level | $317.41 | $2.62 |
| Resistance Level | $345.67 | $3.03 |
| Average True Range (ATR) | 6.52 | 0.17 |
| MACD | 1.39 | -0.02 |
| Stochastic Oscillator | 98.92 | 27.27 |
Price Performance
Historical ComparisonAbout CB Chubb Limited
ACE acquired Chubb in 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in over 50 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.